

Cancer Genomics Improvement Programme (CGIP)

November 2025

Turnaround time for Non-Small Cell Lung Cancer Pathways

Dr Emily Scott

Clinical Research Fellow for the East of England Cancer Alliance

Jo Lowry

Regional Programme Manager, East Genomics Medicine Service Alliance

Sarah Miller

Head of informatics and Performance Improvement, East of England Cancer Alliance

This file is not for wider sharing beyond currently beyond those directly involved. This pack contains sensitive management information and data limitations.

IDEAL end-to-end pathway (solid tumours)

(End-to-end turnaround times)

- Urgent <7 calendar days, for clinically urgent management
- 14 calendar days, for routine diagnosis and genomics to inform first line treatment
- 28 calendar days, for routine diagnosis and genomics to inform subsequent treatment

Clinical

- Tumour sample taken
- Sample preservation
- Request form

Transport to pathology (ideally same day)




Sample/report booking in




Potential transport step

PQAD target: 70% within 10 days by 2024

Histopathology



GLH



CPGC

CPCG: Scrolls / sections cut for genomics, plus test request

Methodology

- Data from up to **30 patients** who had **genomic testing for Non-Small Cell Lung Cancer** between **1 June 2024 and 31 August 2024**
- Pre-genomic (histopathology) → genomic testing → Post-genomic (histopathology)
- 93% return rate from pathology sites across GMSA

Initial Regional Data Overview – East GMSA

East GMSA	N=288	Mean	Median	Mode
Transport to pathology lab		0.4	0	0
Pathology processing	Arrived to booked in	0.2	0	0
	Booked in to post prep	2.7	2	1
	Prepped to first report	5.5	4	1
	First report to genomic request	6.9	0	0
	Genomic request to sent	2.8	1	0
Pathology to Genomics		1.4	1	1
Genomics processing	Arrival to NGS report	9.9	10	13
Genomics to pathology		0.9	0	0
Pathology receipt to clinicians	Receipt to upload to LIMs	1.5	0	0
	Integration to final report	4.1	0	0
	Final report read by clinicians	14	14	0
Total TAT	Available	41.1	26	27
	Read	45.3	39	35

Outputs

Reflex Testing (requesting genomic testing once a diagnosis of cancer is made)

- ▷ Address unwarranted variation in reflex genomic testing

Collaboration and Oversight

- ▷ Work with NHS England & Pathology networks to review Pathology challenges:
Cellular Pathology Genomic Centres and Immunohistochemistry testing

Local Trust Initiatives

- ▷ With report: encourage local teams to review their pathology pathways

Data and Transparency

- ▷ Developing a genomic dashboard for the East Genomic Medicine Service Alliance

Acknowledgements and Key Contacts

We wish to say a huge thank you to all of those who helped with this large data collection. The results will alter patient pathways and improve overall care.

- Dr Emily Scott, Clinical Oncologist and Project Lead for CGIP, East GMSA
emily.scott5@nhs.net
- Professor Dick Sandford, East GMSA Clinical Director
r.sandford@nhs.net
- Emmanuel Ncube, East GMSA Strategy Director
emmanuel.ncube@nnuh.nhs.uk
- Jo Lowry, East GMSA Regional Programme Manager
jo.lowry@uhl-tr.nhs.uk
- Sarah Miller, Head of Informatics and Performance Improvement, East of England Cancer Alliance
Sarah.miller14@nhs.net